Date: 2017-07-19
Type of information: Nomination
Compound: board of directors
Company: Sutro Biopharma (USA - CA)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 19, 2017, SutroVax announced the appointment of Moncef Slaoui, PhD, to the company’s Board of Directors. Dr. Slaoui recently retired following a nearly 30-year career at GSK, during which time he oversaw research and development as Chairman of GSK R&D, served on the board, and most recently built the GSK vaccine division into the lead position in the industry as the Chairman of GSK Vaccines.
During Dr. Slaoui’s tenure at GSK, he was instrumental in reorganizing the company’s R&D structure to facilitate innovation and improve productivity. He was directly involved in the discovery, development and oversight of GSK’s vaccine pipeline, which was the most productive source of vaccines in the industry — yielding 14 new vaccines in the past decade and assembling the broadest portfolio of vaccines (48), of any company, with nearly a billion doses distributed annually.
Dr. Slaoui received a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium, and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. He was a professor of Immunology at the University of Mons, Belgium and is a member of the advisory board of the Qatar Foundation and on the board of the International AIDS Vaccine Initiative.
Financial terms:
Latest news:
Is general: Yes
